No description available.

No description available.

A indoleamina 2,3-dioxigenase (IDO) desempenha um papel importante na tolerância materno-fetal devido á sua ação de catabolizar o triptofano e, consequentemente, impedir a proliferação de linfócitos T, que necessitam desse aminoácido para se manter. Hormônios da reprodução também participam do processo de sobrevivência do feto alogênico, como a progesterona que bloqueia o estímulo mitogênico da proliferação de células T, modula a produção de anticorpos, favorece a produção de IL-10, etc. e o estradiol, que pode modular o perfil imune Th1 ou Th2 na gestação, dependendo de sua concentração. Contudo, a existência ou não de correlação da ação da IDO com esses hormônios ou vice-versa ainda encontra-se pouco evidenciada. Desta forma este trabalho verificou a influência da expressão da IDO e às ações de hormônios da reprodução e citocinas no ciclo celular de células oriundas de fetos e placenta de gestação a termo de fêmeas de ratas e camundongos em cultivo. Este estudo foi realizado em complementação a um trabalho anterior, no qual foi realizada uma avaliação da expressão da IDO por citometria de fluxo em células uterinas, de placentas e de embriões de ratas e camundongos fêmeas prenhes e não prenhes que foram mantidas em cultivo e suplementadas com estradiol, progesterona, interferon γ, triptofano e 1-metil-DL- triptofano. A avaliação das fases do ciclo celular foi realizada pela citometria de fluxo. De acordo com os resultados, em relação ao efeito dos tratamentos no comportamento das células no ciclo celular, podemos observar que, em ratas prenhes e não prenhes, ao adicionar estradiol, houve maior predominância das células em fase G1 nos períodos de 4 e 24 horas, bem como no grupo de camundongos fêmeas prenhes. Algumas células uterinas de ratas não prenhes tratadas com estradiol, assim como as tratadas com progesterona e interferon γ progrediram no ciclo para fase de síntese nos tempos de 24 e 48 horas. Com a adição de triptofano podemos notar nos grupos de ratas não prenhes, camundongos fêmeas prenhes e não prenhes, um aumento da quantidade de células na fase G1 nos três períodos analisados. No grupo de ratas prenhes foi observado uma predominância celular em fase G1 nos tempos de 4 e 24 horas, sendo que em 48 horas, as células sofreram fragmentação de DNA. As células que foram suplementadas com 1- metil DL - triptofano + triptofano mantiveram o mesmo comportamento no ciclo celular , se mantendo em fase G1 nos tempos de 4, 24 e 48 horas grupos prenhes e não prenhes de ratas e nos tempos de 4 e 24 horas nos grupos de camundongos fêmeas prenhes e não prenhes, estando com seu DNA fragmentado e em fase de síntese, respectivamente, no tempo de 48 horas. A suplementação dos diversos fatores aos cultivos celulares permitiu observar alterações na dinâmica do ciclo celular, representada principalmente por um aumento de células em fase G1 nos grupos de células placentárias e embrionárias que receberam progesterona, estradiol, interferon γ e triptofano e apresentaram um significativo aumento da expressão de IDO, e que permite inferir que provavelmente a síntese de RNAm esteja correlacionada à produção da IDO. / The indoleamine 2,3-dioxygenase (IDO) plays an important role in maternal-fetal tolerance due to its capacity to catabolize tryptophan and thereby preventing the proliferation of T lymphocytes, necessary for their maintenance. Reproductive hormones are also involved in the process of survival of semi-allogeneic fetus, as progesterone that blocks mitogenic stimulation of T cell proliferation, modulates antibodies production, promotes production of IL-10, etc. and estradiol, that can modulate the Th1 or Th2 immune profile during pregnancy, depending on its concentration. However, there is very few evidences regarding a possible correlation between IDO expression and these hormones; thus this study examined the influence of the expression of IDO and the actions of reproductive hormones and cytokines in the cell cycle of cells derived from fetuses and placenta at term gestation of female rats and mice in culture. This study was conducted as a complement to an earlier work, in which an evaluation was made of the IDO expression by flow cytometry in uterine cells, placentas and embryos of pregnant rats and mice and non-pregnant females that were maintained in culture and supplemented with estradiol, progesterone, interferon γ, tryptophan and 1-methyl-DLtryptophan. The cell cycle evaluation was conducted by flow cytometry. According to the results, regarding the effect of treatments on the behavior of the cells in the cell cycle, it was observed that in pregnant and non-pregnant rats after the addition of estradiol, there is a greater predominance of cells in G1 phase at periods of 4 and 24 hours, that also was noted in the group of pregnant female mice. Uterine cells from non-pregnant female rats treated with estradiol and progesterone as well as treated with interferon γ progressed to the phase of synthesis on the cycle, at 24 and 48 hours. With the addition of tryptophanin the groups of non-pregnant rats, pregnant and non-pregnant mice , an increased amount of cells in the G1 phase were observed in the three periods analyzed. In the group of pregnant rats a predominance of cells in the G1 phase was observed in periods of 4 and 24 hours, and 48 hours, where the cells undergone DNA fragmentation. In pregnant and non-pregnant rats the cells supplemented with 1 - methyl - DL - tryptophan + tryptophan remained at G1 phase in periods of 4, 24 and 48 hours and 4 and 24 hours for cells from pregnant and non-pregnant mice , that show ragmented DNA followed by synthesis at 48 hours period. Supplementation of the various factors to cell cultures allowed to observe dynamic changes in the cell cycle, represented primarily by an increase of cells in G1 phase in groups of embryonic and placental cells that received progesterone, estradiol, interferon γ and tryptophan and showed a significant increase in the expression of IDO, that allows us to infer that the mRNA synthesis is probably correlated to the production of IDO.

Chronic kidney disease (CKD), a reduction in kidney function, has reached pandemic proportions and imposes a major healthcare burden worldwide. A hallmark of CKD is the accumulation of several chemical compounds, called uremic toxins, which inflict systemic and renal-specific damage. Of the known uremic toxins, kynurenine (Kyn) is known to be particularly vasculotoxic and is implicated in several complications of CKD. Indoleamine 2,3-dioxygenase 1 (IDO), which catalyzes the first step in the metabolism of Tryptophan (Trp), regulates immune response to inflammatory cytokines in tissues. IDO plays a role in apoptosis and damage during acute kidney injury (AKI), a transient decrease in kidney function. During metabolism of Trp, IDO generates Kyn, a uremic solute, and therefore IDO may play a role in the brain and kidney damage due to accumulation of Kyn. The objective of the current study was to investigate the role and regulation of IDO in CKD pathology. Studies were performed to determine whether IDO is protective or pathologic and to find how IDO is regulated in the kidney during CKD. IDO in renopathology was examined using murine models of CKD. CKD was induced via a 0.2% adenine-supplemented diet (AD) model for 21 days. IDO regulation was examined using an Indoxyl Sulfate (IS)-specific solute model. Renal function in the IDO+/+ and IDO-/- AD mice was assessed through weekly measurement of blood urea nitrogen (BUN). H&E and Masson’s trichrome stains were used to assess percentages of glomerulosclerosis (GS) and immune infiltration (II), and combined interstitial fibrosis and tubular atrophy (IFTA) score in IDO+/+ and IDO-/- mice with and without CKD. IDO protein concentration in the kidneys of all mice with and without CKD and IDO+/+ IS mice was determined via immunoblotting. Patients with kidney disease suffer from neuropsychological disorders and neurocognitive decline. The effects of uremic solutes on the CNS was examined using immortalized human umbilical endothelial vein cells (HUVEC-TERT), in vitro. Cell proliferation and viability, in the presence of IS, were measured by BrdU and Alamar blue assays, respectively. In both IDO+/+ and IDO-/-, 21 days of AD results in significant deterioration of renal function. The average IFTA score and percentage of II in IDO-/- mice increased with AD compared to ND (p<0.05, p<0.001). IDO expression was seen sporadically in the glomeruli and walls of major vessels in the kidneys of 4d AD IDO+/+ mice, and in the tubules and vessel walls in the kidneys of 14d AD IDO+/+ mice. In IDO+/+ ND mice, endogenous IDO protein expression was undetectable at a signal intensity of 119.86 ± 268.01, whereas IDO+/+ AD mice showed a 370-fold higher level of IDO protein expression compared to IDO+/+ ND (p<0.001). IDO-/- AD IDO protein expression was 9.5-fold higher than in IDO-/- AD (p<0.05). IDO expression was found to be 58-fold higher in IDO+/+ mice with IS treatment (p<0.05). In the IS mice, non-significant trends toward decrease in cellular proliferation and viability with time were also observed (p=ns). IDO is upregulated at the protein level both in a CKD model and directly by the uremic solute, IS. IDO appears to be protective in the kidney during CKD, given the trend toward increased percentage of GS and II in IDO-/- compared to IDO+/+ mice with CKD, though there is little difference seen in total kidney IFTA. IDO upregulation is linked to increased apoptosis. Blocking uremic solute production would therefore prevent IDO protein upregulation and reduce apoptosis, alleviating renal damage during CKD.

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第21957号 / 医博第4499号 / 新制||医||1037(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 河本 宏, 教授 濵﨑 洋子, 教授 武藤 学 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

京都大学 / 0048 / 新制・課程博士 / 博士(薬学) / 甲第17862号 / 薬博第793号 / 新制||薬||236(附属図書館) / 30682 / 京都大学大学院薬学研究科医療薬科学専攻 / (主査)教授 髙倉 喜信, 教授 橋田 充, 教授 佐治 英郎 / 学位規則第4条第1項該当 / Doctor of Pharmaceutical Sciences / Kyoto University / DFAM

No description available.

No description available.

Yes / Alopecia areata (AA) is an autoimmune hair loss disease with infiltration of proinflammatory cells into hair follicles. Current therapeutic regimens are unsatisfactory mainly because of the potential for side effects and/or limited efficacy. Here we report that cultured, transduced fibroblasts, which express the immunomodulatory molecule indoleamine 2,3-dioxygenase (IDO), can be applied to prevent hair loss in an experimental AA model. A single intraperitoneal (IP) injection of IDO-expressing primary dermal fibroblasts was given to C3H/HeJ mice at the time of AA induction. While 60–70% of mice that received either control fibroblasts or vehicle injections developed extensive AA, none of the IDO-expressing fibroblast-treated mice showed new hair loss up to 20 weeks post injection. IDO cell therapy significantly reduced infiltration of CD4+ and CD8+ T cells into hair follicles and resulted in decreased expression of TNF-α, IFN-γ and IL-17 in the skin. Skin draining lymph nodes of IDO fibroblast-treated mice were significantly smaller, with more CD4+ CD25+ FoxP3+ regulatory T cells and fewer Th17 cells than those of control fibroblast and vehicle-injected mice. These findings indicate that IP injected IDO-expressing dermal fibroblasts can control inflammation and thereby prevent AA hair loss. / Canadian Institutes of Health Researches (Funding Reference Number: 134214 and 136945).

Il existe plusieurs défis au développement d’une thérapie visant à stimuler l’immunité cellulaire. Dans la prévention contre certains virus et en immunothérapie du cancer, l’induction de lymphocytes T spécifiques est cependant primordiale. Dans la première partie de l’étude, nous avons porté notre attention sur la compréhension de la présentation croisée par le complexe majeur d’histocompatibilité de classe I (CMH I) médiée par des particules pseudo-virales (VLP) composées de la protéine de surface de potexvirus à laquelle nous avons ajouté un épitope de la protéine M1 du virus de l’influenza ou un épitope de la protéine gp100 du mélanome. Cette VLP se caractérise par sa capacité à stimuler, sans l’aide d’adjuvant, le système immunitaire et de présenter de façon croisée l’épitope inséré dans sa protéine de surface et ce, indépendamment de l’activité du protéasome. Nous avons, tout d’abord, comparé les propriétés de présentation antigénique croisée des VLP formées du virus de la mosaïque de la malva (MaMV) à celles des VLP du virus de la mosaïque de la papaye (PapMV). Les résultats confirment que ces propriétés sont partagées par plusieurs membres de la famille des potexvirus malgré des divergences de séquences (Hanafi et al. Vaccine 2010). De plus, nous avons procédé à des expériences pour préciser le mécanisme menant à la présentation de l’épitope inséré dans les VLP de PapMV. Les résultats nous confirment une voie vacuolaire dépendante de l’activité de la cathepsine S et de l’acidification des lysosomes pour l’apprêtement antigénique. L’induction de l’autophagie par les VLP semble également nécessaire à la présentation croisée par les VLP de PapMV. Nous avons donc établi un nouveau mécanisme de présentation croisée vacuolaire dépendant de l’autophagie (Hanafi et al. soumis Autophagy). En second lieu, en immunothérapie du cancer, il est aussi important de contrôler les mécanismes d’évasion immunitaire mis en branle par la tumeur. Nous avons spécifiquement étudié l’enzyme immunosuppressive indoleamine 2,3-dioxygénase (IDO) (revue de la littérature dans les tumeurs humaines; Hanafi et al. Clin. Can. Res 2011) et son inhibition dans les cellules tumorales. Pour ce faire, nous avons tenté d’inhiber son expression par la fludarabine, agent chimiothérapeutique précédemment étudié pour son activité inhibitrice de l’activation de STAT1 (signal transducers and activators of transcription 1). Étonnamment, nos résultats ont montré l’inhibition d’IDO dans les cellules tumorales par la fludarabine, indépendamment de l’inhibition de la phosphorylation de STAT1. Nous avons démontré que le mécanisme d’action dépendait plutôt de l’induction de la dégradation d’IDO par le protéasome (Hanafi et al. PlosOne 2014). Les travaux présentés dans cette thèse ont donc portés autant sur la compréhension d’une nouvelle plateforme de vaccination pouvant médier l’activation de lymphocytes T CD8+ cytotoxiques et sur le contrôle d’une immunosuppression établie par les cellules tumorales pour évader au système immunitaire. Ces deux grandes stratégies sont à considérer en immunothérapie du cancer et la combinaison avec d’autres thérapies déjà existantes pourra permettre une meilleure réponse clinique. / There are several challenges to the development of therapies aimed at stimulating cellular immunity. In viral infection prevention and in cancer immunotherapy, the induction of specific T lymphocytes is, however, of paramount importance. In the first part of this study, we focused our attention on understanding the major histocompatibility complex class I (MHC I) cross-presentation mediated by virus-like particles (VLP) composed of potexvirus coat protein, in which we had inserted an epitope from the M1 protein of the Influenza virus or an epitope from gp100, a tumour antigen of melanoma. This particular VLP is characterized by its ability to stimulate the immune system with no adjuvant and its cross-presentation of the inserted epitope independently of proteasome activity. First, we compared the antigenic cross-presentation properties of Malva mosaic virus (MaMV) VLPs to that of Papaya mosaic virus (PapMV) VLPs. The results confirm that cross-presentation mechanisms are shared among different members of the potexvirus family despite marked differences in their sequences (Hanafi et al. Vaccine 2010). Furthermore, we have conducted experiments to clarify the mechanism leading to the cross-presentation of the inserted epitope in PapMV VLPs. The results confirm a vacuolar pathway dependent on cathepsin S activity and on lysosomal acidification for antigen presentation. Autophagy induction by VLPs is also important to PapMV VLP antigen cross-presentation. We have herein described a new vacuolar MHC I cross-presentation pathway dependent on autophagy (Hanafi et al. in preparation). Secondly, in cancer immunotherapy, it is crucial to control immune evasion mechanisms that are initiated by the tumour. We have specifically studied the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) (human cancer literature review in Hanafi et al. Clin. Can. Res. 2011), and its inhibition in tumour cells. To this end, we inhibited its expression using fludarabine, a chemotherapeutic agent previously studied for its inhibitory effect on STAT1 (signal transducers and activators of transcription 1) phosphorylation. Surprisingly, our results demonstrate that IDO inhibition in cancer cells by fludarabine was independent of STAT1 phosphorylation. We showed that the mechanism of action was rather dependent on the induction of IDO degradation by the proteasome (Hanafi et al. PlosOne 2014). The work presented in this thesis provides a better understanding of how a new vaccine platform can mediate cytotoxic CD8+ T lymphocytes activation and the control of the problem of immunosuppression by tumour cells for the evading of the immune system. These two main strategies are to key for the consideration of cancer immunotherapy in combination with other existing therapies, as these should allow a better clinical response to cancer treatment.